Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitravatinib - Mirati Therapeutics

Next Previous
Drug Profile

Sitravatinib - Mirati Therapeutics

Alternative Names: IND-155305; MG-516; MG91516; MGCD-0516; MGCD-516; Sitravatinib-malate; Sitravatinib-malate-Mirati-Therapeutics

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Developer BeOne Medicines; Cancer Research UK; Columbia University; Fudan University; Mirati Therapeutics; University Health Network; University of Birmingham
  • Class Amides; Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorobenzenes; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; Proto-oncogene protein c-ret inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE-2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase II/III Solid tumours
  • Phase II Biliary cancer; Cholangiocarcinoma; Liposarcoma; Liver cancer; Oesophageal cancer; Soft tissue sarcoma; Squamous cell cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Gastric cancer

Most Recent Events

  • 25 Sep 2025 Mirati Therapeutics completes a phase-II/III trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in USA (PO) (NCT04887870)
  • 30 May 2025 Updated efficacy and adverse events data from a phase II trial in Liver cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 06 May 2025 Mirati Therapeutics completes a phase II SITISVEAL trial in Uveal melanoma (Metastatic disease, Combination therapy, Second-line therapy or greater) in Spain (PO) (NCT05542342)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top